National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedEdwards JK, Cole SR, Breger TL
Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population.
This study examined 5-year mortality for adults entering human immunodeficiency virus (HIV) care under universal early treatment compared with the general US population. A total of 82,766 adults entering HIV treatment at North American AIDS Cohort Collaboration clinical sites in the United States were used to compute mortality over 5 years. The authors used NCHS data to construct a cohort representing a subset of the US population matched to study participants on key characteristics. For the study period of 1999 to 2017, the 5-year mortality among adults with HIV was 7.9% higher than expected based on the US general population. Under universal early treatment, the elevation in mortality for people with HIV would have been 7.2%. During the most recent calendar period examined (2011-2017) the elevation in mortality for people with HIV was 2.6% under observed treatment patterns and 2.1% under universal early treatment.
AHRQ-funded; 90047713.
Citation: Edwards JK, Cole SR, Breger TL .
Five-year mortality for adults entering human immunodeficiency virus care under universal early treatment compared with the general US population.
Clin Infect Dis 2022 Sep 14;75(5):867-74. doi: 10.1093/cid/ciab1030..
Keywords: Human Immunodeficiency Virus (HIV), Mortality, Outcomes
Salinas JL, Rentsch C, Marconi VC
Baseline, time-updated, and cumulative HIV care metrics for predicting acute myocardial infarction and all-cause mortality.
The researchers studied prediction rates of myocardial infarction in those with HIV. They found that the Veterans Aging Cohort Study (VACS) Index provided better acute myocardial infarction and mortality prediction than CD4 count and HIV-1 RNA, concluding that current health determines risk more accurately than prior history.
AHRQ-funded; HS018372.
Citation: Salinas JL, Rentsch C, Marconi VC .
Baseline, time-updated, and cumulative HIV care metrics for predicting acute myocardial infarction and all-cause mortality.
Clin Infect Dis 2016 Dec 1;63(11):1423-30. doi: 10.1093/cid/ciw564.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Mortality, Heart Disease and Health, Risk
King JT, Perkal MF, Rosenthal RA
Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators.
The researchers explored the current relationship between perioperative mortality and indicators of immune function, anemia, and hypoalbuminemia among HIV-infected and uninfected individuals. Among HIV-infected patients receiving antiretroviral therapy, modern postoperative mortality rates are low and lower CD4 cell counts are associated with increased mortality, but characteristics other than HIV status, such as age and hypoalbuminemia, are also important determinants of outcome.
AHRQ-funded; HS021112.
Citation: King JT, Perkal MF, Rosenthal RA .
Thirty-day postoperative mortality among individuals with HIV infection receiving antiretroviral therapy and procedure-matched, uninfected comparators.
JAMA Surg 2015 Apr;150(4):343-51. doi: 10.1001/jamasurg.2014.2257..
Keywords: Healthcare Cost and Utilization Project (HCUP), Mortality, Human Immunodeficiency Virus (HIV), Hospitalization, Surgery
Samji H, Cescon A, Hogg RS
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
The researchers estimated changes in life expectancy among HIV-positive adults on antiretroviral therapy (ART) from 2000–2007 in the U.S. and Canada. They concluded that a 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70s, a life expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4 count remain.
AHRQ-funded; 290010012.
Citation: Samji H, Cescon A, Hogg RS .
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
PLoS One 2013 Dec 18;8(12):e81355. doi: 10.1371/journal.pone.0081355..
Keywords: Human Immunodeficiency Virus (HIV), Mortality